{"entity":{"id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of tovecimig, fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and fluorouracil (5-FU) in colorectal cancer, run by Washington University School of Medicine, not yet recruiting.","summary":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07662031 by Washington University School of Medicine, with a registry enrolment figure of 25 participants, started 2026-08-31 and due to reach its primary completion in 2030-08-31. Interventions recorded: Tovecimig; Irinotecan; Leucovorin; 5-Fluorouracil (5-FU). Conditions listed: Colorectal Cancer; Metastatic Colorectal Cancer. Primary outcome: Overall Response Rate (ORR). Colorectal eligibility wording from the registry: \"Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07662031","url":"https://clinicaltrials.gov/study/NCT07662031"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["tovecimig","folfiri","folfox","fluorouracil"],"companies":["compass-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07662031","phase":"2","setting":"A Phase 2 Clinical Trial of Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","sponsor":"Washington University School of Medicine","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07662031/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/"}],"company":[{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}